NURIX THERAPEUTICS INC (NRIX) Stock Analyst Ratings
USA - NASDAQ:NRIX - US67080M1036 - Common Stock
12.26 USD
-0.36 (-2.85%)
11.91 USD
-0.35 (-2.85%)
ChartMill assigns a Buy % Consensus number of 84% to NRIX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 28.62. This target is 133.42% above the current price.
NRIX was analyzed by 24 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about NRIX.
In the previous month the buy percentage consensus was at a similar level.
NRIX was analyzed by 24 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-04 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-04 | Needham | Reiterate | Buy -> Buy |
| 2025-10-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-23 | BTIG | Maintains | Buy -> Buy |
| 2025-10-23 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-22 | Needham | Maintains | Buy -> Buy |
| 2025-10-21 | Mizuho | Initiate | Outperform |
| 2025-10-20 | Needham | Reiterate | Buy -> Buy |
| 2025-10-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-14 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-10 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-10-10 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-07-31 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2025-07-15 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-10 | UBS | Maintains | Buy -> Buy |
| 2025-07-10 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-07-10 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-04-29 | Needham | Reiterate | Buy -> Buy |
| 2025-04-09 | Needham | Maintains | Buy -> Buy |
| 2025-04-09 | Stifel | Maintains | Buy -> Buy |
| 2025-04-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-17 | Leerink Partners | Initiate | Market Perform |
| 2025-02-03 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-01-29 | Needham | Maintains | Buy -> Buy |
| 2025-01-29 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-01-29 | Stifel | Maintains | Buy -> Buy |
| 2025-01-29 | JP Morgan | Maintains | Overweight -> Overweight |
NURIX THERAPEUTICS INC / NRIX FAQ
What is the average price target for NURIX THERAPEUTICS INC (NRIX) stock?
24 analysts have analysed NRIX and the average price target is 28.62 USD. This implies a price increase of 133.42% is expected in the next year compared to the current price of 12.26.
Can you provide the consensus rating for NURIX THERAPEUTICS INC stock?
The consensus rating for NURIX THERAPEUTICS INC (NRIX) is 84.1667 / 100 . This indicates that analysts generally have a positive outlook on the stock.